What is the recommended buprenorphine titration schedule for induction and maintenance in opioid use disorder?

Buprenorphine Titration Schedule for Opioid Use Disorder

Begin buprenorphine induction with 8 mg on Day 1 and advance to 16 mg on Day 2, then continue 16 mg daily for maintenance, initiating only after objective moderate withdrawal (COWS ≥8) appears—at least 4 hours after short-acting opioids or 12–24 hours (ideally longer) after fentanyl or long-acting opioids. 1

Pre-Induction Assessment and Timing

Withdrawal Confirmation Required

• Do not initiate buprenorphine until objective moderate opioid withdrawal is documented using the Clinical Opioid Withdrawal Scale (COWS ≥8). 2
• Premature administration precipitates severe withdrawal because buprenorphine's high μ-receptor affinity displaces full agonists while providing only partial agonist activity. 2

Timing Based on Last Opioid Use

Short-acting opioids (heroin, oxycodone, hydrocodone):

• Wait minimum 4 hours after last use before first dose. 1

Fentanyl:

• Wait minimum 12–24 hours, though many clinicians now extend this interval because fentanyl accumulates in tissue and has unpredictable pharmacokinetics. 2
• A 5-day interval since last fentanyl dose provides sufficient clearance for conventional induction, though this is often impractical. 2

Long-acting opioids (methadone):

• Wait minimum 24 hours, preferably longer, as these patients are more susceptible to precipitated and prolonged withdrawal. 1
• Patients on methadone >30 mg daily face higher withdrawal risk during transition. 1

Standard Induction Protocol (Days 1–2)

Day 1

• Start with 8 mg sublingual buprenorphine (or buprenorphine-naloxone if maintenance formulation is used). 1
• Alternative: Give 4 mg initially, then reassess after 30–60 minutes; if no precipitated withdrawal occurs, administer additional 2–4 mg increments as needed. 2
• Target total Day 1 dose: approximately 8–16 mg depending on withdrawal severity and patient response. 2, 1

Day 2

• Advance to 16 mg as a single daily dose. 1
• This rapid titration is recommended because gradual induction over several days led to high dropout rates in clinical studies. 1

Monitoring During Induction

• Reassess withdrawal status 30–60 minutes after each dose increment. 2
• Frequently monitor level of consciousness and respiratory status, as buprenorphine's variable μ-receptor dissociation can cause unpredictable effects. 2
• Have naloxone readily available to manage unexpected severe withdrawal. 2

Maintenance Dosing (Day 3 Onward)

Standard Maintenance Regimen

• Continue 16 mg daily as the recommended target maintenance dose. 1
• The effective therapeutic range is 12–24 mg daily, adjusted to individual response. 2
• The general maintenance range is 4–24 mg buprenorphine per day. 1
• Doses higher than 24 mg have not demonstrated clinical advantage. 1

Formulation Selection

• Switch to buprenorphine-naloxone (combination product) for maintenance starting Day 3, as the naloxone component deters injection misuse. 2, 1
• Use buprenorphine-only formulations only for patients who cannot tolerate naloxone (e.g., documented hypersensitivity). 1

Dose Adjustments

• Adjust in 2–4 mg increments/decrements to suppress withdrawal symptoms and retain patients in treatment. 1
• Base adjustments on clinical response, not arbitrary schedules. 1

Modified Low-Dose Approach for Fentanyl Exposure

For patients with recent fentanyl use in mild-to-moderate withdrawal:

• Consider multiple 2 mg buprenorphine-naloxone doses to reduce precipitated withdrawal risk. 2
• This microdosing strategy allows gradual receptor transition while original opioids may still be present. 2

Administration Technique

• Place tablets under the tongue until completely dissolved—do not chew, cut, or swallow. 1
• Advise patients not to eat or drink until tablet dissolves. 1
• For doses requiring >2 tablets, place all at once or two at a time under tongue. 1
• Maintain consistent administration method to ensure bioavailability consistency. 1

Supervision and Follow-Up

Early Treatment Phase

• Begin with supervised daily dosing, progressing to unsupervised administration only as clinical stability permits. 1
• See patients at least weekly during the first month. 1
• Do not provide multiple refills early in treatment without appropriate follow-up visits. 1

Prescription Quantity Considerations

• Assess patient's stability level, home security, and ability to manage take-home medication before prescribing unsupervised doses. 1

Duration of Treatment

• No maximum recommended duration exists—patients may require treatment indefinitely. 1
• Continue as long as patients benefit and treatment contributes to goals. 1
• Methadone and buprenorphine decrease opioid-associated and all-cause mortality in OUD. 3

Critical Safety Considerations

Avoid These Medications During Buprenorphine Treatment

• Do not prescribe mixed agonist-antagonist opioids (pentazocine, nalbuphine, butorphanol) in patients on buprenorphine, especially extended-release formulations, as they can precipitate acute withdrawal. 2

Concurrent Substance Use

• Methamphetamine co-use does not contraindicate buprenorphine initiation. 2

Documentation Requirements

• Record objective withdrawal findings using validated scale (COWS) before first dose. 2
• Document elapsed time since last opioid use. 2